Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-&#945; inhibitors upon achieving stable disease activity in rheumatoid arthritis patients.

Aletaha, Daniel; Snedecor, Sonya J; Ektare, Varun; Xue, Mei; Bao, Yanjun; Garg, Vishvas

Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients.

Aletaha, Daniel; Snedecor, Sonya J; Ektare, Varun; Xue, Mei; Bao, Yanjun; Garg, Vishvas.

Afiliação

Aletaha D; Division of Rheumatology, Department of Internal Medicine, Medical University of Vienna, Vienna, Austria.
Snedecor SJ; Pharmerit International, Bethesda, MD.
Ektare V; Pharmerit International, Bethesda, MD.
Xue M; Pharmerit International, Bethesda, MD.
Bao Y; AbbVie Inc., North Chicago, IL, USA.
Garg V; AbbVie Inc., North Chicago, IL, USA.

Clinicoecon Outcomes Res ; 9: 451-458, 2017.

Article em En | MEDLINE | ID: mdl-28814890

Palavras-chave

biologics withdrawal; dose reduction; economic analysis; flare

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Aspecto: Determinantes_sociais_saude Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Áustria

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google